Drug
GEMCIS
GEMCIS is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Active, not recruiting1
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
active_not_recruiting133%
completed133%
terminated133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_2
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
NCT04308174
completedphase_2
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours
NCT02591030
terminatedphase_2
PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
NCT01374789
Clinical Trials (3)
Showing 3 of 3 trials
NCT04308174Phase 2
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
NCT02591030Phase 2
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours
NCT01374789Phase 2
PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3